Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


18.12.2017

2 Am J Obstet Gynecol
10 Ann Oncol
1 BMC Cancer
1 Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
1 Gynecol Oncol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Obstet Gynecol

  1. RUIZ MP, Huang Y, Hou JY, Tergas AI, et al
    All-Cause Mortality in Young Women with Endometrial Cancer Receiving Progesterone Therapy.
    Am J Obstet Gynecol. 2017 Aug 24. pii: S0002-9378(17)30942.
    PubMed     Text format     Abstract available

  2. ABRAMOWICZ JS, Timmerman D
    Ovarian mass-differentiating benign from malignant. The value of the International Ovarian Tumor Analysis (IOTA) ultrasound rules.
    Am J Obstet Gynecol. 2017 Jul 20. pii: S0002-9378(17)30861.
    PubMed     Text format     Abstract available


    Ann Oncol

  3. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  4. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  5. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  6. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  7. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  8. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  9. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  10. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  11. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available

  12. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available


    BMC Cancer

  13. DU J, Shi HR, Ren F, Wang JL, et al
    Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    BMC Cancer. 2017;17:851.
    PubMed     Text format     Abstract available


    Cancer Res

  14. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  15. UCCELLA S, Gisone B, Stevenazzi G, Ghezzi F, et al
    Laparoscopic sentinel node detection with ICG for early ovarian cancer: Description of a technique and literature review.
    Eur J Obstet Gynecol Reprod Biol. 2017 Dec 6. pii: S0301-2115(17)30543.
    PubMed     Text format    


    Gynecol Oncol

  16. GRAYBILL WS, Pothuri B, Chase DM, Monk BJ, et al
    Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30724.
    PubMed     Text format    


    PLoS One

  17. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeilinger R, et al
    Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2017;12:e0189641.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: